Transcriptional expression of Epstein‐Barr virus genes and proto‐oncogenes in North African nasopharyngeal carcinoma

Sbih-Lammali, Fatima; Djennaoui, Djamel; Belaoui, H.; Bouguermouh, A; Decaussin, G.; Ooka, Tadamasa

doi:10.1002/(sici)1096-9071(199605)49:1<7::aid-jmv2>3.3.co;2-u

Cited by 3 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As previously reported in other studies, the serum profile of anti-EBV antibodies was not identical in the two age groups of NPC patients [13,21]. Serum levels of anti-VCA and EA IgG were significantly lower in the juvenile form whereas the anti-EA and VCA IgA were undetectable (<10) in majority of young patients (Table 2).…”

Section: Resultssupporting

confidence: 71%

EBV latent membrane protein 1 abundance correlates with patient age but not with metastatic behavior in north African nasopharyngeal carcinomas

Khabir

Karray

Rodriguez

et al. 2005

Virol J

View full text Add to dashboard Cite

Background: Undifferentiated nasopharyngeal carcinomas are rare in a majority of countries but they occur at a high incidence in South China and to a lesser extent in North Africa. They are constantly associated with the Epstein-Barr virus (EBV) regardless of patient geographic origin. In North Africa, the distribution of NPC cases according to patient age is bi-modal with a large group of patients being around 50 years old (80%) and a smaller group below 25 years old. We and others have previously shown that the juvenile form of NPC has distinct biological characteristics including a low amount of p53 and Bcl2 in the tumor tissue and a low level of anti-EBV IgG and IgA in the peripheral blood.

show abstract

Section: Resultssupporting

confidence: 71%

EBV latent membrane protein 1 abundance correlates with patient age but not with metastatic behavior in north African nasopharyngeal carcinomas

Khabir

Karray

Rodriguez

et al. 2005

Virol J

View full text Add to dashboard Cite

show abstract

“…Based on patterns of expression of the EBV genome, three types of latent gene expression have been described: latency I, II, and III (Table 1). During latency I, Epstein-Barr nuclear antigen 1 (EBNA-1) and the two small noncoding Epstein-Barr RNAs (EBERs) are expressed [9]. EBV gene expression in latency II is usually limited to EBNA-1, the EBERs, latent membrane protein (LMP)-1, and LMP-2A and LMP-2B [10].…”

Section: Ebv Products and Patterns Of Ebv Gene Expressionmentioning

confidence: 99%

“…Latency III usually involves the unrestricted expression of all EBNAs, EBERs, and LMPs [10]. Latency I is generally associated with the EBV-related Burkitt's lymphoma [9], latency II has been associated with classic Hodgkin's lymphoma (cHL) and Tcell non-Hodgkin's lymphoma (NHL) [11], and latency III occurs mainly in immunocompromised individuals suffering from post-transplant lymphoproliferative disorders (PTLDs) and HIV-associated lymphoproliferative disorders and in lymphoblastoid cell lines [12].…”

Section: Ebv Products and Patterns Of Ebv Gene Expressionmentioning

confidence: 99%

EBV-Associated Lymphoproliferative Disorders: Classification and Treatment

2008

View full text Add to dashboard Cite

Since its discovery as the first human tumor virus, Epstein-Barr virus (EBV) has been implicated in the development of a wide range of B-cell lymphoproliferative disorders, including Burkitt's lymphoma, classic Hodgkin's lymphoma, and lymphomas arising in immunocompromised individuals (post-transplant and HIV-associated lymphoproliferative disorders). T-cell lymphoproliferative disorders that have been reported to be EBV associated include a subset of peripheral T-cell lymphomas, angioimmunoblastic Tcell lymphoma, extranodal nasal type natural killer/ T-cell lymphoma, and other rare histotypes. EBV encodes a series of products interacting with or exhibiting homology to a wide variety of antiapoptotic molecules, cytokines, and signal transducers, hence promoting EBV infection, immortalization, and transformation. However, the exact mechanism by which EBV promotes oncogenesis is an area of active debate. The focus of this review is on the pathology, diagnosis, classification, and pathogenesis of EBVassociated lymphomas. Recent advances in EBV cellbased immunotherapy, which is beginning to show promise in the treatment of EBV-related disorders, are discussed. The Oncologist 2008;13:577-585

show abstract

“…Depending on the pattern of molecular expression, several types of latencies are distinguished ( Table 1). [35][36][37][38][39][40][41][42] The virus can enter a latency 3 again in lytic reactivations. 23,34 When viral replication is needed, a type 1 latency is adopted.…”

Section: The Lytic Phasementioning

confidence: 99%

Epstein–Barr Virus in Cutaneous Pathology

Fernández-Flores

2013

The American Journal of Dermatopathology

View full text Add to dashboard Cite

Epstein-Barr virus (EBV) is a ubiquitous double-stranded DNA gamma herpes virus and it is present in 95% of adults. EBV infection is seen in many oncological conditions, although there is controversy regarding whether EBV is causative, a cofactor, or just a coincidental infection. Some of these conditions involve the skin as the main or as a secondary organ. In this report, we review several tumoral and nontumoral cutaneous conditions, which are related to EBV infection, and describe the epidemiology of infection and the life cycle of the virus.

show abstract

Transcriptional expression of Epstein‐Barr virus genes and proto‐oncogenes in North African nasopharyngeal carcinoma

Cited by 3 publications

References 12 publications

EBV latent membrane protein 1 abundance correlates with patient age but not with metastatic behavior in north African nasopharyngeal carcinomas

EBV latent membrane protein 1 abundance correlates with patient age but not with metastatic behavior in north African nasopharyngeal carcinomas

EBV-Associated Lymphoproliferative Disorders: Classification and Treatment

Epstein–Barr Virus in Cutaneous Pathology

Contact Info

Product

Resources

About